These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 7253775)

  • 21. Computational strategies unravel and trace how liver disease changes hepatic drug disposition.
    Park S; Ropella GE; Kim SH; Roberts MS; Hunt CA
    J Pharmacol Exp Ther; 2009 Jan; 328(1):294-305. PubMed ID: 18948498
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Renal function and pharmacotherapy in children].
    Jovanović O
    Srp Arh Celok Lek; 1995 Jun; 123 Suppl 1():15-21. PubMed ID: 18193796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Altered functions and expressions of drug transporters in liver, kidney and intestine in disorders of local and remote organs: possible role of oxidative stress in the pathogenesis.
    Ikemura K; Iwamoto T; Okuda M
    Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):907-20. PubMed ID: 19619071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Influence of disease on the metabolism and effects of drugs in man].
    Lavigne JG
    Union Med Can; 1980 Dec; 109(12):1718-22. PubMed ID: 7210314
    [No Abstract]   [Full Text] [Related]  

  • 27. [Dosage of drugs with regard to their distribution volume and biological half-life].
    Dahl SG
    Tidsskr Nor Laegeforen; 1974 Jun; 94(18):1201-2. PubMed ID: 4839999
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug disposition in liver disease.
    Fruncillo RJ
    Am Fam Physician; 1982 Dec; 26(6):167-9. PubMed ID: 7148640
    [No Abstract]   [Full Text] [Related]  

  • 29. Emerging evidence of the impact of kidney disease on drug metabolism and transport.
    Nolin TD; Naud J; Leblond FA; Pichette V
    Clin Pharmacol Ther; 2008 Jun; 83(6):898-903. PubMed ID: 18388866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of the volume of distribution from in vitro data and use for estimating the absolute extent of absorption.
    Ritschel WA; Hammer GV
    Int J Clin Pharmacol Ther Toxicol; 1980 Jul; 18(7):298-316. PubMed ID: 7429676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Disease as one of many variables affecting drug disposition and response: alterations of drug disposition in liver disease.
    Vesell ES
    Drug Metab Rev; 1978; 8(2):265-91. PubMed ID: 363385
    [No Abstract]   [Full Text] [Related]  

  • 32. The effects of liver and renal dysfunction on the pharmacokinetics of sedatives and analgesics in the critically ill patient.
    Yogaratnam D; Miller MA; Smith BS
    Crit Care Nurs Clin North Am; 2005 Sep; 17(3):245-50. PubMed ID: 16115532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Disorders of pharmacokinetics in pathological states and their clinical significance].
    Orzechowska-Juzwenko K; Bolanowski M; Janicki AG
    Pol Tyg Lek; 1984 Dec 17-31; 39(51-52):1681-6. PubMed ID: 6522322
    [No Abstract]   [Full Text] [Related]  

  • 35. Terminal half-lives of drugs studied in patients with hepatic diseases.
    Closson RG
    Am J Hosp Pharm; 1977 May; 34(5):520-4. PubMed ID: 326043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Problems in dose finding from the view of the clinical pharmacologist (author's transl)].
    Weber E
    Arzneimittelforschung; 1977 Feb; 27(2A):264-72. PubMed ID: 577173
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basic pharmacokinetic principles and their application to psychotropic drugs.
    Greenblatt DJ
    J Clin Psychiatry; 1993 Sep; 54 Suppl():8-13; discussion 55-6. PubMed ID: 8407859
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug misadventuring in neonatal nephrology.
    Fanos V; Cataldi L
    Pediatr Med Chir; 2002; 24(2):150-6. PubMed ID: 11987523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The use of the concepts of "half-life" and "clearance" in practice and in pharmacokinetics].
    Raaflaub J
    Schweiz Med Wochenschr; 1981 Sep; 111(38):1406-11. PubMed ID: 7280641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.